Part of: S&P 100 · Healthcare & Devices · Income & Dividends

Abbott Laboratories (ABT)

AI-powered earnings call analysis for Abbott Laboratories. Get insights from quarterly earnings reports with our AI-generated podcast. Educational content only - not investment advice.

20 episodes 5 languages

Next Episode

Abbott Laboratories earnings call scheduled for Jan 28, 2027 (before market open)

New episode expected Jan 29, 2027

Latest Episode

Q3 2026 Earnings

6:53 • 10/21/2026

Abbott Laboratories (ABT) - Q3 2026

0:00

6:53

Speed:

Q3 2026 Earnings

8:34 • 2026/10/21

Abbott Laboratories (ABT) - Q3 2026

0:00

8:34

Speed:

Q3 2026 Earnings

11:48 • 21/10/2026

Abbott Laboratories (ABT) - Q3 2026

0:00

11:48

Speed:

Q3 2026 Earnings

7:47 • 21/10/2026

Abbott Laboratories (ABT) - Q3 2026

0:00

7:47

Speed:

Q3 2026 Earnings

7:58 • 21.10.2026

Abbott Laboratories (ABT) - Q3 2026

0:00

7:58

Speed:

All Episodes

EN - English (4) CN - 中文 (4) FR - Français (4) ES - Español (4) DE - Deutsch (4)

Q3 2026 Earnings

6:53

Abbott reported Q3 2026 with 7% sales growth and 9% EPS growth, while announcing plans to spin off its $8.5B nutrition business by end of 2027 to focus on higher-growth healthcare markets.

Q2 2026 Earnings

6:36

Abbott raised FY EPS guidance to $5.45-$5.60 on Q2 beat of $1.31 EPS and 4.8% sales growth, reaffirming 6.5%-7.5% sales guidance with momentum from nutrition, EP, diagnostics, and Libre.

Q1 2026 Earnings

8:14

Abbott delivered Q1 adjusted EPS of $1.15 (+6% YoY) with 3.7% comparable sales growth, completed Exact Sciences acquisition on 03/23/2026, and raised FY2026 comparable sales guidance to 6.5%-7.5% with EPS midpoint of $5.48.